This website provides information about laboratory diagnostic services. The analyses presented are not a therapy and do not replace medical diagnosis and treatment. Medical decisions are made exclusively by your attending physician.
Fasting mimicking diet oncology investigates metabolic interventions as a potential approach to resensitize therapy-resistant tumors. Fasting mimicking diet cancer therapy, metabolic intervention cancer, differential stress resistance cancer cells, valter longo fasting cancer and nutrient deficiency tumor cell therapy together form the scientific basis for this innovative research approach, which is based on 30 years of juventology research.
The metabolic intervention tumor uses the phenomenon of differential stress resistance: healthy cells protect themselves under nutrient deficiency, while differential stress resistance tumor cells shows that cancer cells become more susceptible. Valter longo fasting therapy tumor approaches may enable the resensitization of resistant tumors.
nutrient deficiency cancer cell treatment exploits fundamental differences between healthy cells and tumor cells. This innovative interwencja metaboliczna rak research opens up new perspectives for oncology.
Liquid Biopsy: Personalized tumor diagnostics in practical implementation
A CONGRESS LECTURE BY DR. RER. NAT. DANIEL HEYLMANN, IQMEDIX
Which therapy works - and why? How molecular tumor profiles can change treatment decisions.
Liquid Biopsy is a minimally invasive procedure for the analysis of circulating tumor cells (CTCs) in the blood. Instead of a surgical procedure, a blood sample is taken – and thus opens up the possibility of continuously monitoring the molecular activity of a tumor over the entire course of the disease.
The focus is on the question of how specific, individually suitable therapy options can be derived from CTC-based gene expression profiles – as an evidence-based guide for doctors and therapists that takes into account both complementary and conventional medical approaches.
Metabolic intervention cancer – basics of FMD research
Metabolic intervention cancer is based on the principle that tumor cells and healthy cells react differently to a lack of nutrients. Metabolic intervention tumor concepts make targeted therapeutic use of this biological difference. Research into metabolic intervention cancer shows promising results in overcoming resistance to therapy.
Differential stress resistance – Why cancer cells become more vulnerable
Differential stress resistance of cancer cells describes the core phenomenon of FMD research: when deprived of nutrients, healthy cells activate protective programs, whereas cancer cells cannot. Differential stress resistance makes tumor cells selectively vulnerable to attack. This differential stress resistance of cancer cells is the scientific key to the therapeutic potential of FMD.
Valter Longo Fasting Cancer – 30 years of juventology research
Valter longo fasting cancer research is revolutionizing our understanding of metabolism and tumor biology. Valter longo fasting therapy tumor approaches are being investigated in clinical trials for their effectiveness as a supplement to standard therapy. Valter longo fasting cancer findings open up new perspectives for integrative oncology.
Nutrient deficiency in tumour cells – resensitization of therapy-resistant tumours
Nutrient deficiency tumor cell therapy aims to overcome resistance mechanisms of cancer cells. In combination with chemotherapy or immunotherapy, nutrient deficiency tumor cell therapy can improve the effectiveness of existing treatments. Targeted nutrient-deficient tumor cell therapy is a promising approach in modern oncology.
The vision
Liquid Biopsy in clinical practice
In the following video presentation from the 3rd iQMedix Therapy Congress, you will learn how circulating tumor cells are extracted from a simple blood sample and analyzed molecularly – and how an individual gene expression profile is created from this, on the basis of which therapy options are derived. Dr. Heylmann, cancer researcher and Head of Molecular Biology Diagnostics at iQMedix, will show how CTC-based profiles provide doctors and therapists with a molecular map of the tumor – for therapy options that take into account both complementary and conventional medical therapies. The presentation will also provide an insight into the process from blood collection to the final report and the two analysis options iSELECT and iComplete.
NOTE: The following video documents a specialist congress lecture. The contents represent the scientific discourse and are not a therapy recommendation. Therapeutic applications require official approval and medical supervision.
MOLECULAR DIAGNOSTICS AND SCIENTIFIC QUESTIONS
What circulating tumor cells reveal about your patient
How does Liquid Biopsy differ from a conventional biopsy?
While a classic biopsy requires a surgical procedure, a simple blood sample is taken during a Liquid Biopsy. The procedure enables continuous monitoring over the entire course of the disease - without repeated invasive procedures.
What do circulating tumor cells reveal about the tumor process?
The presence and, in some tumor types, the concentration of circulating tumor cells (CTCs) in the blood are associated with an unfavorable prognosis and a higher risk of metastasis. Changes in the CTC count during the course of therapy can - depending on the tumor entity, stage and measurement method - provide indications of therapy response (decrease in CTC count) or disease progression (increase), but do not replace diagnostic imaging.
How are tumor cells isolated from the blood?
Isolation is carried out in several steps: Density centrifugation, lysis of red blood cells and negative selection using magnetically coupled antibodies. This is followed by RNA extraction.
What does the gene expression profile show - and what therapies can be derived from it?
After isolation, a molecular activity profile of the tumor is created using RT-qPCR. Highly expressed genes indicate which signaling pathways are active - and which therapeutic substances, whether complementary or conventional, could potentially be effective based on this profile.
What do iSelect and iComplete stand for - and how do they differ?
iSelect analyzes up to 35 gene expressions with a focus on natural substances and repurposed drugs - as a starting point for patients in the early stages or for supplementary diagnostics. iComplete extends the profiling to 85 genes and also covers the entire spectrum of conventional medicine: from chemotherapeutics to targeted therapies and immunotherapies.
Process & results
From blood to findings: from the blood sample to the findings report
HOW DOES THE SAMPLE LOGISTICS WORK?
For the analysis, 40 ml of blood is taken from the patient. iQMedix provides a blood collection kit for this purpose and organizes the collection of the sample within a time window of two hours – to ensure that the blood sample is transported to the laboratory within one day. Circulating tumor cells are isolated by density centrifugation, lysis of red blood cells and negative selection with magnetic beads.
WHAT EXACTLY DOES THE REPORT CONTAIN?
The report lists therapeutic substances based on the individual gene expression profile – evaluated according to their potential efficacy on the specific tumor. In the iSELECT report, this includes natural substances and repurposed drugs. The iComplete report expands this to include approved chemotherapeutics, targeted therapies, immunotherapies and hormone therapies – divided into three categories: Evidence for Sensitivity, Low Sensitivity and Evidence for Resistance.
WITHIN WHAT TIME WILL THE RESULTS BE AVAILABLE?
Once the blood sample has been received by the laboratory, the finished report is typically available within 10 to 15 working days – as a structured guide that brings together molecular data, current specialist literature and the individual patient’s medical history.
Liquid Biopsy in action: What you can expect in the video
MOLECULAR DIAGNOSTICS IN PRACTICE
What does a real iComplete report look like – and how do you read it? In the video, Dr. Heylmann navigates live through a specific patient profile and shows examples of how gene expressions and treatment options are related. An insight that no flyer can replace.
HOW DOES THE GENE EXPRESSION PROFILE INFLUENCE THE TREATMENT OPTIONS IN THE REPORT?
Which genes are highly active in this tumor – and what does this mean, for example, for the choice between a tyrosine kinase inhibitor, immunotherapy or a complementary approach? The lecture makes the molecular decision-making logic behind the diagnostic report transparent and clinically tangible.
HOW IS AN IQMEDIX REPORT STRUCTURED?
Dr. Heylmann answers this question in the video using specific examples and explains which parts of the report have what meaning and make it easy to understand.
Personalized approaches in cancer diagnostics
iQMedix’s research vision – to better understand and provide targeted support for cancer through innovative Liquid Biopsy diagnostics and individualized molecular profiles – is increasingly becoming a clinical reality thanks to scientific developments such as CTC-based gene expression analysis.
Your knowledge advantage starts here:
Vitamins are considered a natural part of a healthy diet. But in oncology, a more complex question arises: do they support the patient – or
Liquid Biopsy is a minimally invasive procedure for the analysis of circulating tumor cells (CTCs) in the blood. Instead of a surgical procedure, a blood
The focus is on the question of how healthy cells and cancer cells behave differently under nutrient deficiency – a phenomenon known as “differential stress
Ferroptosis provides a scientific background for the different responses to vitamin C therapies.
The latest developments make it clear that we are on the threshold of a new era in cancer diagnostics.
Scientific tumor lectures from the Therapeutic Congress May 2025. Expert lecture on tumor diagnostics & oncology.
Molecular precision cancer therapy is revolutionizing tumour medicine. Precision medicine & personalized therapy for better chances of recovery.
